NEW YORK (GenomeWeb) – Health information company Sema4 said today that it plans to leverage GNS Healthcare's machine learning and simulation platform in its drug discovery and development pipelines.

The companies plan to first focus on discovering the underlying drivers of cardiovascular disease and identifying existing drugs to treat it as well as opportunities for developing novel therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.